Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.67 |
| ▸ | NAAA | Q02083 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2167965 | 1.00 | HRH1 (0.67) | HRH1NAAACYP1A2SMN1; SMN2CYP2C19 | |
| SCHEMBL2167104 | 1.00 | HRH1 (0.67) | HRH1NAAACYP1A2SMN1; SMN2CYP2C19 | |
| SCHEMBL7878429 | 1.00 | HRH1 (0.67) | HRH1NAAACYP1A2SMN1; SMN2CYP2C19 | |
| SCHEMBL16288588 | 1.00 | HRH1 (0.67) | HRH1NAAACYP1A2SMN1; SMN2CYP2C19 | |
| SCHEMBL8499503 | 1.00 | HRH1 (0.67) | HRH1NAAACYP1A2SMN1; SMN2CYP2C19 | |
| SCHEMBL498506 | 0.98 | HRH1 (0.63) | HRH1NAAACYP1A2SMN1; SMN2CYP2C19 | |
| SCHEMBL96246 | 0.92 | HRH1 (0.60) | HRH1NAAACYP1A2SMN1; SMN2CYP2C19 | |
| SCHEMBL2096007 | 0.90 | HRH1 (0.56) | HRH1NAAACYP1A2SMN1; SMN2CYP2C19 | |
| SCHEMBL4418086 | 0.89 | HRH1 (0.80) | HRH1NAAACYP1A2SMN1; SMN2CYP2C19 | |
| SCHEMBL2843489 | 0.89 | HRH1 (0.80) | HRH1NAAACYP1A2SMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253194-B2 | Compounds and inhibitors of phospholipases | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-08-07 | — | — | US | claimed |
| EP-1309552-A4 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | UNIV QUEENSLAND (AU) | 2005-07-20 | — | — | EP | claimed |
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | QUEENSLAND, THE UNIVERSITY OF (AU) | 2004-02-19 | — | — | US | claimed |
| JP-2004503604-A | — | — | 2004-02-05 | — | — | JP | claimed |
| EP-1309552-A1 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2003-05-14 | — | — | EP | claimed |
| WO-2002008189-A1 | COMPOUNDS AND INHIBITORS OF PHOSPHOLIPASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2002-01-31 | — | — | WO | claimed |
| EP-0503426-B1 | Quinone derivatives | EISAI CO LTD (JP) | 1996-12-27 | — | — | EP | claimed |
| US-5329010-A | Unsaturated groups with heteroarylalkyl groups and carboxy derivatives | EISAI CO., LTD. (JP) | 1994-07-12 | — | — | US | claimed |
| EP-0503426-A1 | Quinone derivatives | Eisai Co., Ltd. (JP) | 1992-09-16 | — | — | EP | claimed |
| EP-4383238-A2 | IRIDIUM COMPLEX COMPOUND, COMPOSITION CONTAINING THE COMPOUND AND SOLVENT, ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THE COMPOUND, DISPLAY DEVICE, AND ILLUMINATION DEVICE | Mitsubishi Chemical Corporation (JP) | 2024-06-12 | — | — | EP | disclosed |
| EP-3719028-B1 | IRIDIUM COMPLEX COMPOUND, COMPOSITION CONTAINING SAID COMPOUND AND SOLVENT, ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING SAID COMPOUND, DISPLAY DEVICE AND ILLUMINATION DEVICE | MITSUBISHI CHEM CORP (JP) | 2024-06-12 | — | — | EP | disclosed |
| CN-113853381-B | Iridium complex compound, composition containing the compound and solvent, organic electroluminescent element containing the compound, display device and lighting device | 三菱化学株式会社 | 2024-06-11 | — | — | CN | disclosed |
| CN-111263766-B | Iridium complex compound, composition containing the compound and solvent, organic electroluminescent element containing the compound, display device and lighting device | 三菱化学株式会社 | 2024-04-02 | — | — | CN | disclosed |
| WO-2024004963-A1 | ORGANIC ELECTROLUMINESCENT LIGHT-EMITTING ELEMENT MATERIAL, ORGANIC ELECTROLUMINESCENT LIGHT-EMITTING ELEMENT, ORGANIC EL DISPLAY DEVICE, ORGANIC EL LIGHTING, ORGANIC ELECTROLUMINESCENT LIGHT-EMITTING ELEMENT-FORMING COMPOSITION, AND METHOD FOR PRODUCING ORGANIC ELECTROLUMINESCENT LIGHT-EMITTING ELEMENT | 三菱ケミカル株式会社 | 2024-01-04 | — | — | WO | disclosed |
| EP-0236140-A2 | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
| EP-0218999-A2 | New quinazoline derivatives, process for their production and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-04-22 | — | — | EP | disclosed |
| EP-0035228-B1 | TETRAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND ANTI-ULCER COMPOSITION CONTAINING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-01-02 | — | — | EP | disclosed |
| US-4477447-A | ANTIBIOTIC, BACTERICIDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-16 | — | — | US | disclosed |
| US-4372953-A | Tetrazole derivatives, and anti-ulcer composition containing the same | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1983-02-08 | — | — | US | disclosed |
| EP-0035228-A1 | Tetrazole derivatives, process for the preparation thereof, and anti-ulcer composition containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1981-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | PLA2G4C, PLA2G4B, PLA2G4A | HRH1 1315/4885NAAA 120/4885CYP1A2 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.